These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Anticoagulants and cancer survival. Piccioli A; Falanga A; Prandoni P Semin Thromb Hemost; 2006 Nov; 32(8):810-3. PubMed ID: 17171594 [TBL] [Abstract][Full Text] [Related]
6. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy? Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525 [TBL] [Abstract][Full Text] [Related]
7. Clinical studies with anticoagulants to improve survival in cancer patients. Gerotziafas GT; Papageorgiou C; Hatmi M; Samama MM; Elalamy I Pathophysiol Haemost Thromb; 2008; 36(3-4):204-11. PubMed ID: 19176993 [TBL] [Abstract][Full Text] [Related]
8. [Cancer, thromboembolia and antithrombotic therapy: is there an anticoagulant of choice?]. Scharf RE Dtsch Med Wochenschr; 2011 Nov; 136(47):2403. PubMed ID: 22094968 [No Abstract] [Full Text] [Related]
9. Non-Vitamin K Oral Anticoagulants (NOACs) A Review of Clinical Management and Laboratory Issues. Blann A Curr Vasc Pharmacol; 2016; 14(3):220-36. PubMed ID: 26059459 [TBL] [Abstract][Full Text] [Related]
10. Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer. Pritchard ER; Murillo JR; Putney D; Hobaugh EC J Oncol Pharm Pract; 2019 Jan; 25(1):52-59. PubMed ID: 28825375 [TBL] [Abstract][Full Text] [Related]
11. Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer. Walenga JM; Lyman GH Crit Rev Oncol Hematol; 2013 Oct; 88(1):1-18. PubMed ID: 23849978 [TBL] [Abstract][Full Text] [Related]
12. [Which antithrombotic agents should be prescribed in deep venous thrombosis of the limbs?]. Fiessinger JN Presse Med; 1994 Mar; 23(11):509-10. PubMed ID: 8022737 [TBL] [Abstract][Full Text] [Related]
13. Biological and clinical aspects of anticancer effects of antithrombotics. Falanga A Pathophysiol Haemost Thromb; 2003 Sep-2004 Dec; 33(5-6):389-92. PubMed ID: 15692249 [TBL] [Abstract][Full Text] [Related]
14. Vitamin K antagonists in anticoagulant therapy of patients with cancer. Pasierski T Pol Arch Med Wewn; 2012; 122(1-2):60-4. PubMed ID: 22353708 [TBL] [Abstract][Full Text] [Related]
15. Deep vein thrombosis and cancer: survival, recurrence, and anticoagulant choices. Lee AY Dis Mon; 2005; 51(2-3):150-7. PubMed ID: 15900267 [No Abstract] [Full Text] [Related]
16. [Heparins, antivitamins K. Principles and rules of use. Posology of non-fractionated heparins]. Delsart D; Chambefort V; Decousus H Rev Prat; 2001 Sep; 51(13):1489-97. PubMed ID: 11601082 [No Abstract] [Full Text] [Related]
17. The complex effects of heparins on cancer progression and metastasis in experimental studies. Smorenburg SM; Van Noorden CJ Pharmacol Rev; 2001 Mar; 53(1):93-105. PubMed ID: 11171940 [TBL] [Abstract][Full Text] [Related]
18. 'Sailing in troubled waters': a review of the use of anticoagulation in adult cancer patients with thrombocytopenia. Ibrahim RB; Skewes MD; Kuriakose P Blood Coagul Fibrinolysis; 2016 Sep; 27(6):615-30. PubMed ID: 26945262 [TBL] [Abstract][Full Text] [Related]
19. Antimetastatic activities of heparins and modified heparins. Experimental evidence. Borsig L Thromb Res; 2010 Apr; 125 Suppl 2():S66-71. PubMed ID: 20434009 [TBL] [Abstract][Full Text] [Related]